Induced Pluripotent Stem Cells (iPSC) Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Australia, Brazil, Mexico, Saudi Arabia, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Report ID: GMI4428

Summary Methodology

Induced Pluripotent Stem Cells (iPSC) Market size is projected to experience significant growth from 2019 to 2025.

Induced pluripotent stem cells are directly generated from adult human cells that are genetically reprogrammed to express the properties of embryonic stem cells. These cells can be used to produce cells or body tissues required for treatment of wide array of diseases such as leukemia, spinal cord injury, diabetes among other chronic disorders. These cells have limited immune rejection and are derived from the patient itself without causing them much harm. 

Induced Pluripotent Stem Cells (iPSC) Market, By Cell Type
Induced Pluripotent Stem Cells (iPSC) Market

Get more details on this report - Request Free Sample PDF

The global induced pluripotent stem cells (iPSC) market is forecasted to witness significant growth across the forecast timeframe. High growth is due increasing investment in R&D activities to explore new applications of induced pluripotent stem cells by government and private organizations. For instance, as per the NIH estimates, the total fund granted for research programs of induced pluripotent stem cells (iPSC) amounted to USD 335 million. Hence, growing government and private funding for research projects will foster industry growth in the future.  

Increasing number of clinical trials by majority of the players will be one of the chief factors propelling industry growth. Major players such as Cynata Therapeutics, Fate Therapeutics among others are focusing on R&D activities to develop novel therapeutics using induced pluripotent stem cells. For instance, in November 2018, Fate Therapeutics announced that it received U.S. FDA approval for investigational new drug application of FT500, a natural killer (NK) cell product candidate derived from induced pluripotent stem cell (iPSC) line. Aforementioned factors will spur industry growth across the forecast timeframe.

The cell type segment includes neuronal cells, cardiac cells, vascular cells, immune cells, renal cells, liver cells and other. Cardiac cells segment is expected to witness substantial growth over the forecast period. The use of iPSC-derived cardiomyocytes is gaining popularity for use in multiple experiments. Wide array of applications such as drug screening, cardiotoxicity testing, drug validation along with electrophysiology applications and metabolism studies is the primary growth factor. Additionally, consistent results and ability to maintain pure-cultures for long-term experimentations are other advantages of iPSC-derived cardiac cells, thereby augmenting segmental growth.

The application segment is bifurcated into academic research, drug development, regenerative medicine, toxicity testing and others. The drug development segment is expected to show significant growth during the analysis period. Various companies are involved in development of novel therapies and drugs for chronic disorders. For instance, Cynata Therapeutics announced successful completion of Phase-1 clinical trials of CYP-001. The compound is intended for treatment of steroid-resistant acute graft versus host disease. With increasing number of market players initiating clinical studies, the market for drug development is forecasted to expand considerably in the future.

The end-use segment consists of hospitals, research institutes and biotechnology companies. Biotechnology companies as an end-use is expected to witness positive growth across the projected years. Various clinical stage biotechnology companies are involved in the development of innovative treatment using induced pluripotent stem cells. Furthermore, increasing clinical trials and R&D activities will augment industry growth. Moreover, growing number of approvals from various regulatory bodies to initiate large scale studies of the use of induced pluripotent stem cells for drug development will spur industry growth.

The North America iPSC market is expected to dominate the overall industry during the forecast period owing to increasing advancements in iPSC technology. Also, steady supply of functional cells for pre-clinical screening of drugs will supplement the market growth. Furthermore, increasing understanding of the unique iPSC platform and high-throughput analyses for drug toxicity will foster industry expansion in the region. Various government funding programs will further support the market expansion in the North American region.

Some of the key industry players include Axol Bioscience Ltd, Cynata Therapeutics, Fate Therapeutics, Ncardia and Reprocell. Key strategies adopted by industry players include strategic collaborations, mergers, innovative product launch and partnerships to expand their business. For instance, in September 2019, Fate Therapeutics announced the opening of its cGMP manufacturing facility for production of its iPSC-derived Natural Killer (NK) cell line. The opening of the manufacturing facility will enable the company to develop large-scale, cost-effective products to meet the growing demand and strengthen its market presence.

Induced Pluripotent Stem Cells (iPSC) Market, By Cell Type, 2014-2025 (USD Million)

  • Neuronal cells
  • Cardiac cells
  • Vascular cells
  • Immune cells
  • Renal cells
  • Liver cells
  • Others

Induced Pluripotent Stem Cells (iPSC) Market, By Application, 2014-2025 (USD Million)

  • Academic research
  • Drug development
  • Regenerative medicine
  • Toxicity testing
  • Others

Induced Pluripotent Stem Cells (iPSC) Market, By End-use, 2014-2025 (USD Million)

  • Hospitals
  • Research institutes
  • Biotechnology companies
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa
    • Saudi Arabia
    • South Africa

Company Profiles:

  • Axol Bioscience Ltd.
  • Cell Applications, Inc
  • Cellular Dynamics, Inc.
  • Cynata Therapeutics
  • Fate Therapeutics
  • Ncardia
  • Reprocell
  • Thermo Fisher Scientific
  • Takara Bio, Inc.

What Information does this report contain?

Historical data coverage: 2016 to 2020; Growth Projections: 2021 to 2027.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Customize this Report

Pre Book Now

Need a Discount? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X